Pfizer NYSE:PFE Stock Price, News & Analysis

Please bear with us as we address this and restore your personalised lists. For the current quarter, Pfizer is expected to post earnings of $0.67 per share, indicating a change of -18.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +4.4% over the last 30 days. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

Does Pfizer look financially stable?

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account.

  • As of Aug. 9, 2021, Pfizer had 5,606,688,356 shares of voting common stock outstanding.
  • CY24 revenue reached $63.6B (+6.7% YoY), with non-COVID sales growing 12%, exceeding expe…
  • Zacks Ranks stocks can, and often do, change throughout the month.
  • On Dec. 11, 2020, the Pfizer-BioNTech vaccine became the first COVID-19 vaccine to receive emergency use authorization (EUA) from the U.S.
  • “On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity drugs.

Although PFE stock presents a degree of risk due to its moderate valuation, our analysis indicates it remains a favorable buy. We estimate Pfizer’s valuation to be around $36 per share, reflecting over 35% upside from its current levels. Pfizer reported revenues of $17.76 billion in the last reported quarter, representing a year-over-year change of +24.7%. For Pfizer, the consensus sales estimate for the current quarter of $13.99 billion indicates a year-over-year change of -6%. For the current and next fiscal years, $63.2 billion and $62.68 billion estimates indicate -0.7% and -0.8% changes, respectively.

Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE)

Explore Pfizer stock price, quotes, charts and forecasts with Benzinga. As of Aug. 9, 2021, Pfizer had 5,606,688,356 shares of voting common stock outstanding. The FDA gave the vaccine full jd edwards stock approval on Aug. 23, 2021, after reviewing the biologics license application (BLA) submitted by Pfizer and BioNTech.

The tariffs thus encompass the grander plan surrounding how the pharmaceutical industry fits into scaling up domestic manufacturing. A majority of pharma and biotech companies have a significant presence in the US. However, some questions still stand, such as whether they will hire more people in the US compared to Europe or Asia and whether they will bring back more business to America. On February 21, Jared Holz, Mizuho Securities America’s healthcare sector strategist, appeared on CNBC to discuss Trump’s tariffs and their effects on the American pharma sector. Buying quality stocks at decent valuations can give you a good margin of safety and minimize your investment risk. And while many stocks trade at cheap valuations because they are highly risky, that isn’t the case with Pfizer.

Ever feel like you missed the boat in buying the most successful stocks? On Oct. 29, 2021, the FDA extended the EUA como invertir en amazon for the vaccine to include children ages 5–11. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. Learn about the world class team who designed and built the Simply Wall St analysis model.

Zen Rating

Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries. Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

How have Pfizer’s revenues grown over recent years?

This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Pfizer remained flat while the S&P 500 dropped 2.25%, reinforcing its defensive strength in a risk-off market. CY24 revenue reached $63.6B (+6.7% YoY), with non-COVID sales growing 12%, exceeding expe… Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday. Dividend growth can be an important tool for income-focused investors to help combat the negative impact that inflation has on one’s buying power. Top institutional shareholders of Pfizer include Vanguard Group Inc. (9.15%), Charles Schwab Investment Management Inc. (2.74%), Wellington Management Group LLP (2.47%) and Geode Capital Management LLC (2.13%).

On May 10, 2021, the FDA expanded the EUA for the Pfizer-BioNTech vaccine to include adolescents ages 12–15. While that range does suggest a modest decline on the top line is likely, the company is still investing in growth opportunities — its growth days are by no means over. PFE stock has fared better than the benchmark S&P 500 index during some of the recent downturns. Our dashboard How Low Can Stocks Go During A Market Crash captures how key stocks fared during and after the last six market crashes.

Additionally, the company has historically outperformed during market downturns, making it a potentially attractive option for investors navigating the current economic uncertainty. However, for investors who seek lower volatility than individual stocks, the Trefis High-Quality portfolio presents an alternative – having outperformed the S&P 500 and generated returns exceeding 91% since its inception. As the Trump administration’s tariff policies create market uncertainty, with the S&P 500 down 6% this year, investors are increasingly seeking safer investments. Our take on market crash risk right now has more details on tariffs and its impact on the broader market.

Pfizer Remains A Good Pick For Dividend Investors

The two companies completed their submission of the BLA in May 2021. It was the first COVID-19 vaccine to receive full approval from the FDA. In 2020, Pfizer co-developed with BioNTech SE a vaccine against COVID-19, the virus whose rapid spread prompted the World Health Organization (WHO) to declare a global pandemic in March 2020. On Dec. 11, 2020, the Pfizer-BioNTech vaccine became the first COVID-19 vaccine to receive emergency use authorization (EUA) from the U.S. The vaccine was approved for emergency use for individuals 16 years of age and older.

This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.89% per year. These returns cover a period from January 1, 1988 through March 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for t… Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New coinberry review York Stock Exchange and on the path to developing today’s blockbuster lineup.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and non-profit The Motley Fool Foundation. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.

Therefore, knowing a company’s potential revenue growth is crucial. For the next fiscal year, the consensus earnings estimate of $2.99 indicates a change of +0.9% from what Pfizer is expected to report a year ago. Pfizer has been a cheap stock for a while, and barring some big development, it’s likely that it’ll take some time before it starts to rally again.

  • Pfizer offers a 6.7% yield, trading at a low valuation with resilient drug portfolio growth and co…
  • These returns cover a period from January 1, 1988 through March 3, 2025.
  • Dividend growth can be an important tool for income-focused investors to help combat the negative impact that inflation has on one’s buying power.
  • In predicting a stock’s future price performance, it’s crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company’s growth prospects.

Currently, the stock trades at a forward price-to-earnings (P/E) multiple of less than 9, based on analysts’ expectations for the year ahead. By comparison, the average stock in the Health Care Select Sector SPDR Fund trades at a forward P/E of nearly 18, making Pfizer look like a deeply discounted stock today. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report.